These findings support the interpretation that stimulation of eIF2α-P by SAL003 overcomes resistance of HER2+ cancers to Trastuzumab (Fig. 6d), but it is currently unclear whether this process depends on the upregulation of P21CIP1 and JNK1/2 activity in the treated tumors. The gene discussed is CDKN1A; the disease is cancer.